Area of research
Oncology · Cancer Research
Research interest
Research interests include PARP inhibition in cancer therapy, Cancer Genomics and Diagnostics, CRISPR and Genetic Engineering, and Ovarian cancer diagnosis and treatment.
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases
Data from Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Rare variant contribution to human disease in 281,104 UK Biobank exomes
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Abstract 3503: Biomarkers for inhibitors of the replication stress response proteins WEE1 and ATR in triple negative breast cancer
Abstract 932: Reversing PARP inhibitor resistance by targeting the replication stress response
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
AKT Inhibition in Solid Tumors With <i>AKT1</i> Mutations
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
CALIBRATE: Intensive profiling of circulating tumour DNA (ctDNA) from patients participating in experimental therapeutics trials including mutational profiles and copy number changes.
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
Genes Contributing to Pain Sensitivity in the Normal Population: An Exome Sequencing Study